{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"MRK","limit":50},"count":50,"signals":[{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":63,"context":"| Non-GAAP (1) | $ | 8.98 | 17 | % | 19 | % | $ | 7.65 | * | * | $ | 1.51 | | * > 100%(1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items from Mercks results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). For furt","filed_date":"2026-02-24","accession":"0000310158-26-000063","full_text":"https://origin.rootz.global/static/filing/0000310158-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":17,"context":"e entered into the latest rounds of VBP had, on average, a price reduction of more than 50%. The Company expects that the VBP process will have a significant impact on mature products moving forward. Emerging Markets The Companys focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls a","filed_date":"2026-02-24","accession":"0000310158-26-000063","full_text":"https://origin.rootz.global/static/filing/0000310158-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":20,"context":"alth care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Companys sales performance in 2025 was negatively affected b","filed_date":"2026-02-24","accession":"0000310158-26-000063","full_text":"https://origin.rootz.global/static/filing/0000310158-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":60,"context":"other opportunities to further its environmental strategy and will evaluate potential impacts and commitments. Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Companys financial condition, results of operations, liquidity or capital resources for any year. Environmental Regulation and Remediation The Company believes that there are no compliance iss","filed_date":"2026-02-24","accession":"0000310158-26-000063","full_text":"https://origin.rootz.global/static/filing/0000310158-26-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":47,"context":"| | | Cost of sales | 3,855 | 4,080 | 10,831 | 11,365 | | | Selling, general and administrative | 2,633 | 2,731 | 7,835 | 7,952 | | | Research and development | 4,234 | 5,862 | 11,903 | 13,354 | | | Restructuring costs | 47 | 56 | 676 | 258 | | | Other (income) expense, net | (238) | (162) | (281) | (151) | | | | 10,531 | 12,567 | 30,964 | 32,778 | | | Income Before Taxes | 6,745 | 4,090 | 17,647 | 15,766 | | | Tax","filed_date":"2025-11-05","accession":"0000310158-25-000059","full_text":"https://origin.rootz.global/static/filing/0000310158-25-000059.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":47,"context":"ther | | | Cost of sales | 3,557 | 3,745 | 6,976 | 7,285 | | | Selling, general and administrative | 2,649 | 2,739 | 5,202 | 5,221 | | | Research and development | 4,048 | 3,500 | 7,669 | 7,492 | | | Restructuring costs | 560 | 80 | 629 | 202 | | | Other (income) expense, net | (7) | 42 | (43) | 12 | | | | 10,807 | 10,106 | 20,433 | 20,212 | | | Income Before Taxes | 4,999 | 6,006 | 10,902 | 11,675 | | | Taxes on In","filed_date":"2025-08-05","accession":"0000310158-25-000014","full_text":"https://origin.rootz.global/static/filing/0000310158-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":30,"context":"15,529 | $ | 15,775 | | | Costs, Expenses and Other | | | Cost of sales | 3,419 | 3,540 | | | Selling, general and administrative | 2,552 | 2,483 | | | Research and development | 3,621 | 3,992 | | | Restructuring costs | 69 | 123 | | | Other (income) expense, net | (35) | (33) | | | | 9,626 | 10,105 | | | Income Before Taxes | 5,903 | 5,670 | | | Taxes on Income | 818 | 903 | | | Net Income | 5,085 | 4,767 | | | Le","filed_date":"2025-05-02","accession":"0001628280-25-021834","full_text":"https://origin.rootz.global/static/filing/0001628280-25-021834.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"rch, development, manufacturing, sales, or marketing of the Companys products or (ii)conduct detrimental to the Company, including the Companys overall goodwill or reputation to the Company, and (b)a significant negative impact on the Companys financial operating results or reputation occurred.  Hedging and Pledging  As part of our insider trading policy, the Company has a policy against the hedging and pledging of Company","filed_date":"2025-04-09","accession":"0001193125-25-076859","full_text":"https://origin.rootz.global/static/filing/0001193125-25-076859.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"urposes of the meeting are to:  1. Elect the 13 Director nominees named in this proxy statement;  2. Consider and act upon a proposal to approve, by non-binding advisory vote, the compensation of our Named Executive Officers;  3. Consider and act upon a proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for 2025;  4. Consider and act upon a shar","filed_date":"2025-04-09","accession":"0001193125-25-076859","full_text":"https://origin.rootz.global/static/filing/0001193125-25-076859.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":55,"context":"n-GAAP (1) | $ | 7.65 | * | * | $ | 1.51 | (80) | % | (75) | % | $ | 7.48 | | * > 100%(1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items from Mercks results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). For furt","filed_date":"2025-02-25","accession":"0001628280-25-007732","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":18,"context":"to be a semi-annual process that will have a significant impact on mature products moving forward. 9 [Table of Content](#i783cf867b028427ba2fa2dcfd656c4d4_7)[s](#i783cf867b028427ba2fa2dcfd656c4d4_7) Emerging Markets The Companys focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls a","filed_date":"2025-02-25","accession":"0001628280-25-007732","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":21,"context":"alth care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Companys sales performance in 2024 was negatively affected b","filed_date":"2025-02-25","accession":"0001628280-25-007732","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":59,"context":"other opportunities to further its environmental strategy and will evaluate potential impacts and commitments. Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Companys financial condition, results of operations, liquidity or capital resources for any year. Environmental Regulation and Remediation The Company believes that there are no compliance iss","filed_date":"2025-02-25","accession":"0001628280-25-007732","full_text":"https://origin.rootz.global/static/filing/0001628280-25-007732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":41,"context":"| | | Cost of sales | 4,080 | 4,264 | 11,365 | 12,214 | | | Selling, general and administrative | 2,731 | 2,519 | 7,952 | 7,700 | | | Research and development | 5,862 | 3,307 | 13,354 | 20,904 | | | Restructuring costs | 56 | 126 | 258 | 344 | | | Other (income) expense, net | (162) | 126 | (151) | 388 | | | | 12,567 | 10,342 | 32,778 | 41,550 | | | Income Before Taxes | 4,090 | 5,620 | 15,766 | 3,935 | | | Taxes o","filed_date":"2024-11-06","accession":"0001628280-24-045689","full_text":"https://origin.rootz.global/static/filing/0001628280-24-045689.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":42,"context":"er | | | Cost of sales | 3,745 | 4,024 | 7,285 | 7,951 | | | Selling, general and administrative | 2,739 | 2,702 | 5,221 | 5,182 | | | Research and development | 3,500 | 13,321 | 7,492 | 17,597 | | | Restructuring costs | 80 | 151 | 202 | 218 | | | Other (income) expense, net | 42 | 172 | 12 | 259 | | | | 10,106 | 20,370 | 20,212 | 31,207 | | | Income (Loss) Before Taxes | 6,006 | (5,335) | 11,675 | (1,685) | | | In","filed_date":"2024-08-05","accession":"0001628280-24-034715","full_text":"https://origin.rootz.global/static/filing/0001628280-24-034715.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":40,"context":"15,775 | $ | 14,487 | | | Costs, Expenses and Other | | | Cost of sales | 3,540 | 3,926 | | | Selling, general and administrative | 2,483 | 2,479 | | | Research and development | 3,992 | 4,276 | | | Restructuring costs | 123 | 67 | | | Other (income) expense, net | (33) | 89 | | | | 10,105 | 10,837 | | | Income Before Taxes | 5,670 | 3,650 | | | Taxes on Income | 903 | 825 | | | Net Income | 4,767 | 2,825 | | | Les","filed_date":"2024-05-03","accession":"0001628280-24-020283","full_text":"https://origin.rootz.global/static/filing/0001628280-24-020283.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"arch, development, manufacturing, sales or marketing of the Companys products or (ii)conduct detrimental to the Company, including the Companys overall goodwill or reputation to the Company, and (b)a significant negative impact on the Companys financial operating results or reputation occurred.  Hedging and Pledging  As part of our insider trading policy, Merck prohibits Directors and management level employees, including o","filed_date":"2024-04-11","accession":"0001193125-24-093204","full_text":"https://origin.rootz.global/static/filing/0001193125-24-093204.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"urposes of the meeting are to:  1. Elect the 12 Director nominees named in this proxy statement;  2. Consider and act upon a proposal to approve, by non-binding advisory vote, the compensation of our Named Executive Officers;  3. Consider and act upon a proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for 2024;  4. Consider and act upon a shar","filed_date":"2024-04-11","accession":"0001193125-24-093204","full_text":"https://origin.rootz.global/static/filing/0001193125-24-093204.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":57,"context":"GAAP (1) | $ | 1.51 | (80) | % | (75) | % | $ | 7.48 | 39 | % | 43 | % | $ | 5.37 | | (1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items from Mercks results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). For furt","filed_date":"2024-02-26","accession":"0001628280-24-006850","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":18,"context":"last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. Emerging Markets The Companys focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls a","filed_date":"2024-02-26","accession":"0001628280-24-006850","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":22,"context":"t of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Companys sales performance in 2023 was negatively affected b","filed_date":"2024-02-26","accession":"0001628280-24-006850","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":61,"context":"other opportunities to further its environmental strategy and will evaluate potential impacts and commitments. Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Companys financial condition, results of operations, liquidity or capital resources for any year. Environmental Regulation and Remediation The Company believes that there are no compliance iss","filed_date":"2024-02-26","accession":"0001628280-24-006850","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"lun-Biotech remains eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100million in Kelun-Biotech shares in January 2023.In January 2023, Merck acquired Imago, a clinical-stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms an","filed_date":"2024-02-26","accession":"0001628280-24-006850","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006850.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":30,"context":"| | | 12,214 | | | 13,530 | | | | Selling, general and administrative | 2,519 | | | 2,520 | | | 7,700 | | | 7,355 | | | | Research and development | 3,307 | | | 4,399 | | | 20,904 | | | 9,773 | | | | Restructuring costs | 126 | | | 94 | | | 344 | | | 288 | | | | Other (income) expense, net | 126 | | | 429 | | | 388 | | | 1,576 | | | | | 10,342 | | | 11,376 | | | 41,550 | | | 32,522 | | | | Income Before Taxes | 5,62","filed_date":"2023-11-03","accession":"0001628280-23-036717","full_text":"https://origin.rootz.global/static/filing/0001628280-23-036717.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":31,"context":"| | | 7,951 | | | 9,596 | | | | Selling, general and administrative | 2,702 | | | 2,512 | | | 5,182 | | | 4,834 | | | | Research and development | 13,321 | | | 2,798 | | | 17,597 | | | 5,374 | | | | Restructuring costs | 151 | | | 142 | | | 218 | | | 194 | | | | Other (income) expense, net | 172 | | | 438 | | | 259 | | | 1,148 | | | | | 20,370 | | | 10,106 | | | 31,207 | | | 21,146 | | | | (Loss) Income Before Taxe","filed_date":"2023-08-07","accession":"0001628280-23-027770","full_text":"https://origin.rootz.global/static/filing/0001628280-23-027770.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":30,"context":"| | | | | | | | Cost of sales | 3,926 | | | 5,380 | | | | | | | | Selling, general and administrative | 2,479 | | | 2,323 | | | | | | | | Research and development | 4,276 | | | 2,576 | | | | | | | | Restructuring costs | 67 | | | 53 | | | | | | | | Other (income) expense, net | 89 | | | 708 | | | | | | | | | 10,837 | | | 11,040 | | | | | | | | Income Before Taxes | 3,650 | | | 4,861 | | | | | | | | Taxes on Income","filed_date":"2023-05-05","accession":"0001628280-23-015990","full_text":"https://origin.rootz.global/static/filing/0001628280-23-015990.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"November 2022. The assessment reaffirmed our belief that our compensation programs and policies are structured and operated in a manner that does not create risks that are reasonably likely to have a material adverse effect on our business. In addition to ongoing monitoring of our programs and policies, we are committed to performing formal assessments on a periodic basis. The next formal assessment is scheduled for rev","filed_date":"2023-04-03","accession":"0001193125-23-089525","full_text":"https://origin.rootz.global/static/filing/0001193125-23-089525.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":69,"context":"urposes of the meeting are to:  1. Elect the 13 Director nominees named in this proxy statement;  2. Consider and act upon a proposal to approve, by non-binding advisory vote, the compensation of our Named Executive Officers;  3. Consider and act upon a proposal to approve, by non-binding advisory vote, the frequency of future votes to approve the compensation of our Named Executive Officers;  4. Consider and act upon a","filed_date":"2023-04-03","accession":"0001193125-23-089525","full_text":"https://origin.rootz.global/static/filing/0001193125-23-089525.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":43,"context":"| 39 | % | | 43 | % | | $ | 5.37 | | | 81 | % | | 98 | % | | $ | 2.97 | | | * > 100%  (1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs, gains and losses from investments in equity securities, and certain other items from Mercks results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). In 2022,","filed_date":"2023-02-24","accession":"0001628280-23-005061","full_text":"https://origin.rootz.global/static/filing/0001628280-23-005061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":18,"context":"last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. Emerging Markets The Companys focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls a","filed_date":"2023-02-24","accession":"0001628280-23-005061","full_text":"https://origin.rootz.global/static/filing/0001628280-23-005061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":21,"context":"t of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Companys sales performance in 2022 was negatively affected b","filed_date":"2023-02-24","accession":"0001628280-23-005061","full_text":"https://origin.rootz.global/static/filing/0001628280-23-005061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"oducts, thereby reducing the amount of waste the Company generates and lowering the Companys production costs. Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Companys financial condition, results of operations, liquidity or capital resources for any year. Environmental Regulation and Remediation The Company believes that there are no compliance iss","filed_date":"2023-02-24","accession":"0001628280-23-005061","full_text":"https://origin.rootz.global/static/filing/0001628280-23-005061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"n, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100million in Kelun-Biotechs Series B preferred shares in January 2023. In January 2023, Merck acquired Imago, a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproli","filed_date":"2023-02-24","accession":"0001628280-23-005061","full_text":"https://origin.rootz.global/static/filing/0001628280-23-005061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":34,"context":"0 | | | 13,530 | | | 9,752 | | | | Selling, general and administrative | 2,520 | | | 2,336 | | | 7,355 | | | 6,804 | | | | Research and development | 4,399 | | | 2,445 | | | 9,773 | | | 9,177 | | | | Restructuring costs | 94 | | | 107 | | | 288 | | | 487 | | | | Other (income) expense, net | 429 | | | (450) | | | 1,576 | | | (1,007) | | | | | 11,376 | | | 7,888 | | | 32,522 | | | 25,213 | | | | Income from Continuin","filed_date":"2022-11-03","accession":"0000310158-22-000034","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"ondensed Consolidated Financial Statements (unaudited) (continued) ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100million in Ornas Series B preferred shares in the fourth quarter of 2022. In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orions inv","filed_date":"2022-11-03","accession":"0000310158-22-000034","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":35,"context":"04 | | | 9,596 | | | 6,303 | | | | Selling, general and administrative | 2,512 | | | 2,281 | | | 4,834 | | | 4,468 | | | | Research and development | 2,798 | | | 4,321 | | | 5,374 | | | 6,732 | | | | Restructuring costs | 142 | | | 82 | | | 194 | | | 380 | | | | Other (income) expense, net | 438 | | | (103) | | | 1,148 | | | (558) | | | | | 10,106 | | | 9,685 | | | 21,146 | | | 17,325 | | | | Income from Continuing","filed_date":"2022-08-05","accession":"0000310158-22-000030","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"m statements have been included and are of a normal and recurring nature.  ReclassificationsCertain reclassifications have been made to prior year amounts to conform to the current year presentation. Spin-Off of Organon & Co. On June 2, 2021, Merck completed the spin-off of products from its womens health, biosimilars and established brands businesses into a new, independent, publicly traded company named Or","filed_date":"2022-08-05","accession":"0000310158-22-000030","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":33,"context":"| | | | | | | | Cost of sales | 5,380 | | | 3,199 | | | | | | | | Selling, general and administrative | 2,323 | | | 2,187 | | | | | | | | Research and development | 2,576 | | | 2,412 | | | | | | | | Restructuring costs | 53 | | | 297 | | | | | | | | Other (income) expense, net | 708 | | | (455) | | | | | | | | | 11,040 | | | 7,640 | | | | | | | | Income from Continuing Operations Before Taxes | 4,861 | | | 2,987 |","filed_date":"2022-05-05","accession":"0000310158-22-000011","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"November 2020. The assessment reaffirmed our belief that our compensation programs and policies are structured and operated in a manner that does not create risks that are reasonably likely to have a material adverse effect on our business. In addition to ongoing monitoring of our programs and policies, we are committed to performing formal assessments on a periodic basis. The next formal assessment is scheduled for rev","filed_date":"2022-04-04","accession":"0001193125-22-095134","full_text":"https://origin.rootz.global/static/filing/0001193125-22-095134.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":76,"context":"ted at-risk before we had any data on clinical efficacy to support manufacturing scale-up so that molnupiravir would be available if regulatory authorizations or approvals were received. We have also entered into licensing agreements to support timely access to molnupiravir globally. For example, Merck has entered into a licensing agreement with the Medicines Patent Pool (MPP) to increase broad access for molnupiravir in 105 low","filed_date":"2022-04-04","accession":"0001193125-22-095134","full_text":"https://origin.rootz.global/static/filing/0001193125-22-095134.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":45,"context":"| | $ | 4.53 | | | 21 | % | | 25 | % | | $ | 3.73 | | | * Calculation not meaningful.  (1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs and certain other items. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS (see Non-GAAP Income and Non-GAAP EPS below). Executive Summary During 2021, Merck delivere","filed_date":"2022-02-25","accession":"0000310158-22-000003","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":18,"context":"last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward. Emerging Markets The Companys focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls a","filed_date":"2022-02-25","accession":"0000310158-22-000003","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":26,"context":"t of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Companys revenue performance in 2021 was negatively affected","filed_date":"2022-02-25","accession":"0000310158-22-000003","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"echnologies help to promote biodiversity and support the global need for reliable and safe sources of protein. Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Companys financial condition, results of operations, liquidity or capital resources for any year. In December 2021, the Company completed its inaugural issuance of a $1.0 billion sustainabilit","filed_date":"2022-02-25","accession":"0000310158-22-000003","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"coImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50million for a 20% ownership interest in the new entity, which was valued at $33million resulting in a $17million premium. Merck also recognized other net liabilities of $22million. The Company recorded Resea","filed_date":"2022-02-25","accession":"0000310158-22-000003","full_text":"https://origin.rootz.global/static/filing/0000310158-22-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":35,"context":"13 | | | 9,752 | | | 8,589 | | | | Selling, general and administrative | 2,336 | | | 2,060 | | | 6,804 | | | 6,336 | | | | Research and development | 2,445 | | | 3,349 | | | 9,177 | | | 7,609 | | | | Restructuring costs | 107 | | | 113 | | | 487 | | | 265 | | | | Other (income) expense, net | (450) | | | (312) | | | (1,007) | | | (637) | | | | | 7,888 | | | 8,223 | | | 25,213 | | | 22,162 | | | | Income from Continu","filed_date":"2021-11-05","accession":"0000310158-21-000032","full_text":"https://origin.rootz.global/static/filing/0000310158-21-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"coImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50million for a 20% ownership interest in the new entity, which was valued at $33million resulting in a $17million premium. Merck also recognized other net liabilities of $22million. The Company recorded Resea","filed_date":"2021-11-05","accession":"0000310158-21-000032","full_text":"https://origin.rootz.global/static/filing/0000310158-21-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":35,"context":"47 | | | 6,303 | | | 5,576 | | | | Selling, general and administrative | 2,281 | | | 2,085 | | | 4,468 | | | 4,276 | | | | Research and development | 4,321 | | | 2,085 | | | 6,732 | | | 4,260 | | | | Restructuring costs | 82 | | | 82 | | | 380 | | | 152 | | | | Other (income) expense, net | (103) | | | (387) | | | (558) | | | (325) | | | | | 9,685 | | | 6,612 | | | 17,325 | | | 13,939 | | | | Income from Continuing","filed_date":"2021-08-09","accession":"0000310158-21-000028","full_text":"https://origin.rootz.global/static/filing/0000310158-21-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"coImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50million for a 20% ownership interest in the new entity, which was valued at $33million resulting in a $17million premium. Merck also recognized other net liabilities of $22million. The Company recorded Resea","filed_date":"2021-08-09","accession":"0000310158-21-000028","full_text":"https://origin.rootz.global/static/filing/0000310158-21-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MRK","company":"Merck & Co., Inc.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"| 2,060 | | |  | 2,619 | | |  | 8,955 | | |  | 9,455 | | | |  Research and development | |  | 2,412 | | |  | 2,175 | | |  | 2,085 | | |  | 3,349 | | |  | 5,788 | | |  | 13,397 | | |  | 9,724 | | | |  Restructuring costs | |  | 297 | | |  | 70 | | |  | 82 | | |  | 113 | | |  | 310 | | |  | 575 | | |  | 626 | | | |  Other (income) expense, net | |  | (455 | ) | |  | 62 | | |  | (387 | ) | |  | (312 | ) | |  | (253 | )","filed_date":"2021-06-21","accession":"0001104659-21-083528","full_text":"https://origin.rootz.global/static/filing/0001104659-21-083528.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"0ace334d817bbb5aca8973c3971cf7212e0893f33c22c237fa82204f148d5e52","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d963e646da3b4eb1ec5b42e4267238c53721eb09582ac6d4f26eaebd23cece16","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":101,"hourly_limit":500,"remaining":399,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}